Vemurafenib improves survival of melanoma patients. However, cutaneous side-effects commonly occur in them. Nivolumab and ipilimumab are monoclonal antibodies against programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4, both of which regulate excessive T-cell activation. Although these agents induce antitumor immunity against melanoma, the modified immune condition may result in an unexpected adverse reaction which has not been observed previously. Herein, we report a case who manifested severe erythema multiforme-like eruption with mucosal involvement associated with vemurafenib following nivolumab. The patient also subsequently suffered from ipilimumab-induced interstitial pneumonia with refractory course. Such a case has never been reported. This case suggested that dermatologists should pay special attention to unexpected adverse events of these drugs, and carefully observe cutaneous and respiratory status of patients during the treatment of melanoma.

作者：Hisashi, Nomura；Hayato, Takahashi；Satsuki, Suzuki；Yuichi, Kurihara；Shotaro, Chubachi；Ichiro, Kawada；Hiroyuki, Yasuda；Tomoko, Betsuyaku；Masayuki, Amagai；Takeru, Funakoshi

来源：The Journal of dermatology 2017 年 44卷 7期